TECNOLOGÍA PARA LA MONITORIZACIÓN Y CONTROL DE LA DIABETES

Volver

Resultados 95 resultados LastUpdate Última actualización 21/09/2017 [20:58:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



previousPage Página2 de 4 nextPage   Mostrar por página


CALIBRATION OF A HANDHELD DIABETES MANAGING DEVICE THAT RECEIVES DATA FROM A CONTINUOUS GLUCOSE MONITOR

NºPublicación: PL2654564T3 31/08/2017

Solicitante:
F HOFFMANN-LA ROCHE AG [CH]

Resumen de: WO2012084157A1

A method for calibrating a handheld diabetes managing device based on data generated by a continuous glucose monitor. The method can include sampling a current of the continuous glucose monitor at a sampling interval over a time period to generate a plurality of current samples for the time period. The method can also include determining a mean, median and standard deviation of the plurality of current samples. The blood glucose level of the patient can be measured at a first time and a calibration equation that associates the plurality of current samples with the estimated glucose level of the patient based on the measured blood glucose level and the plurality of current samples can be determined when the standard deviation is less than a first threshold and an absolute value of a difference between the mean and median is less than a second threshold.



traducir


 

ESTIMATION OF GLUCOSE RATE OF APPEARANCE FROM CGS AND SUBCUTANEOUS INSULIN DELIVERY IN TYPE 1 DIABETES

NºPublicación: WO2017145119A1 31/08/2017

Solicitante:
UNIV KING ABDULLAH SCI & TECH [SA]
PRINCE SULTAN UNIV [SA]

Resumen de: WO2017145119A1

Method and System for providing estimates of Glucose Rate of Appearance from the intestine (GRA) using continuous glucose sensor measurements (CGS) taken from the subcutaneous of a diabetes patient and the amount of insulin administered to the patient.



traducir


 

METERING DEVICE FOR DISPENSING MEDICATION FLUID

NºPublicación: US2017246382A1 31/08/2017

Solicitante:
MEAMEDICAL AG [CH]

Resumen de: US2017246382A1

A metering device for dispensing medication fluid includes: a spindle unit, a drive unit for rotationally driving the spindle unit, and a reservoir for the medication fluid. The reservoir has a wall, which defines a cross-sectional area of the reservoir, and a plunger located in the reservoir. The rotational driving of the spindle unit causes a translational motion of the plunger, and therefore displaces medication fluid. Because the product of the cross-sectional area of the reservoir in the unit mm2 and the spindle pitch in the unit mm/degree is less than 0.13 mm3/degree and the medication fluid is a liquid insulin having a concentration in a range of U20 to U100, a metering system can be formed that is suitable specifically for the CSII therapy of children and youth, where high discharge accuracy is important for good therapy control.



traducir


 

A SYSTEM FOR DECREASING THE BLOOD GLUCOSE LEVEL

NºPublicación: WO2017146658A1 31/08/2017

Solicitante:
CAKMAK YUSUF OZGUR [TR]

Resumen de: WO2017146658A1

Present application discloses a blood glucose level decreasing system that decreases blood glucose level of a patient by blocking the sympathetic innervation to liver and pancreas and the smooth muscles of the arteries reaching to liver and pancreas with non¬ invasive electrostimulation of the skin which have the sympathetic nerves originating from the same spinal cord segments with the liver and pancreas sympathetic innervation. Said blood glucose level decreasing system comprises at least one sensor for measuring the blood glucose level of said patient; at least two electrodes that are placed to skin dermatomal of said patient; at least one stimulator that sends electrical signals to said electrodes in order to block the sympathetic nerve innervation to smooth muscles of hepatic artery proper and liver, and expand liver artery of the patient; and at least one control unit, which receives the blood glucose level from said sensor, compares received level with a predetermined threshold value and control said stimulator according to the result of said comparison.



traducir


 

Gradual and Individualized Transitions between Drug Delivery Protocols in an Ambulatory Drug Delivery System

NºPublicación: US2017249444A1 31/08/2017

Solicitante:
JOHN MICHAEL SASHA [US]

Resumen de: US2017249444A1

A drug infusion system located at least partially external to the patient having a pump and an external patient programmer control configured to allow adjustment of therapy. Adjustment may include setting, selecting and adjusting the transition period between drug delivery rates. The system can present to the patient an alert related to the adjustment and receive patient input information in response thereto. A patient response rule module is configured to apply a rule to the input information provided by a patient. For example, the patient response rule can be used to provide an insulin pump setting according to the patient response rule or to provide a setting, or to provide a setting that is proposed to the user. Other systems and methods are also described such as asking questions related to the adjustment of future therapy settings.



traducir


 

SYSTEMS FOR PERIPHERAL NERVOUS STIMULATION FOR METABOLIC AND ENDOCRINE FUNCTION

NºPublicación: WO2017147282A1 31/08/2017

Solicitante:
VERILY LIFE SCIENCES LLC [US]

Resumen de: WO2017147282A1

Systems are provided for neuro stimulation. In one implementation, a system is provided that includes a stimulator introduced into tissue at a target location and a central controller that communicates wirelessly with the stimulator. The stimulator includes a power system that receives wireless energy transmission, and an electrode system that transmits an electrical pulse for stimulating the target location. The central controller includes a power system that wirelessly delivers power to the stimulator, a communication system that wirelessly communicates with the stimulator, and a processing system that controls the power system and the communication system. The central controller may instruct the stimulator to transmit one or more electrical pulses to the target location to affect an endocrine function (e.g., affect the glucose level of a patient).



traducir


 

METHOD FOR PREDICTION OF DEGREE OF RISK OF POLYCYSTIC OVARIAN SYNDROME FORMATION IN ADOLESCENT GIRLS

NºPublicación: RU2629720C1 31/08/2017

Solicitante:
GOSUDARSTVENNOE BYUDZHETNOE OBRAZOVATELNOE UCHREZHDENIE VYSSHEGO PROFESSIONALNOGO OBRAZOVANIYA KURSK [RU]

Resumen de: RU2629720C1

FIELD: medicine.SUBSTANCE: invention can be used to predict the risk of polycystic ovarian syndrome (PCOS) formation in adolescent girls. As anamnestic data assess the presence of: hereditary burden on PCOS by both mother and father, burdened family history of type 2 diabetes, burdened heredity for obesity are estimated. The presence of each attribute is scored as 2 points. Also the presence of low ≤2800 g or high ≥4000 g body weight of the child at birth at mature gestation term, maternal gestational diabetes during pregnancy, excess of the mother's body weight during pregnancy, chronic tonsilogenous infections and frequent sore throats, traumatic brain injury, history of neuroinfection, sedentary lifestyle, severe psychoemotional stress in the girl are determined. If present, the attributes are scored as 1 point each. Among the clinical data the presence of: menstrual irregularities in the type of oligo-/amenorrhea for more than 1.5-2 years after menarche, anovulatory cycle, obesity - body mass index (BMI) more than 30 kg/m, hirsutism is estimated. The presence of each attribute is scored as 3 points. If there is an excess of body weight with a BMI of 26-30 kg/m, abdominal redistribution of fat deposits, borderline hairiness - 8-14 points on the Ferriman-Gallwey scale, increased greasiness of hair and skin, acne, seborrhea, negroid acanthosis, fibrocystic mastopathy, 2 points are assigned to each feature. 1 point is assigned to the presence of normal body weight, dysfun



traducir


 

SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM

NºPublicación: US2017245801A1 31/08/2017

Solicitante:
DEXCOM INC [US]

Resumen de: US2017245801A1

Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.



traducir


 

SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM

NºPublicación: US2017245802A1 31/08/2017

Solicitante:
DEXCOM INC [US]

Resumen de: US2017245802A1

Systems and methods for minimizing or eliminating transient non-glucose related signal noise due to non-glucose rate limiting phenomenon such as ischemia, pH changes, temperatures changes, and the like. The system monitors a data stream from a glucose sensor and detects signal artifacts that have higher amplitude than electronic or diffusion-related system noise. The system replaces some or the entire data stream continually or intermittently including signal estimation methods that particularly address transient signal artifacts. The system is also capable of detecting the severity of the signal artifacts and selectively applying one or more signal estimation algorithm factors responsive to the severity of the signal artifacts, which includes selectively applying distinct sets of parameters to a signal estimation algorithm or selectively applying distinct signal estimation algorithms.



traducir


 

INFUSION PREPARATION

NºPublicación: EP3210598A1 30/08/2017

Solicitante:
OTSUKA PHARMACEUTICAL FACTORY INC [JP]

Resumen de: EP3210598A1

An object of the present invention is to provide an infusion preparation in which the Maillard reaction between an amino acid and a reducing sugar does not occur during storage and the size of fat particles in the fat emulsion does not increase during storage, and in which various types of vitamins can be incorporated in a stable manner, in spite of the fact that it is a two-chamber infusion preparation. Furthermore, even if only one of the infusions (of the infusion preparation) is administered, the patient is unlikely to develop hyperkalemia, vascular pain, or phlebitis. The present invention provides an infusion preparation containing two chambers separated by a partition that can be communicably opened, wherein a first chamber contains a first-chamber infusion containing a sugar and a fat emulsion, a second chamber contains a second-chamber infusion containing an amino acid and an electrolyte, the first-chamber infusion is substantially free of potassium, and has a relative osmotic pressure of 2.0 to 3.0, the second-chamber infusion has a potassium concentration of 40 mEq/L or less and a relative osmotic pressure of 2.5 to 3.5, and a mixture of the first- and second-chamber infusions has a potassium concentration of 16 mEq/L or more as measured upon communicably opening the partition.



traducir


 

Apparatus, system and method for validating images of a phantom

NºPublicación: GB2547775A 30/08/2017

Solicitante:
GOLD STANDARD PHANTOMS LTD [GB]

Resumen de: GB2547775A

Data from one or more sensors measuring parameters associated with the operating state of a phantom during a scan 47 is input to a computer model 48, which is used to produce reference image data. This is compared with the acquired image 49 in order to return a pass/fail score, indicating acceptability of imaging system calibration. Synchronization 45 may occur before image acquisition. The measured parameters may be, for example, phantom fluid flow rate, pressure, pH or concentration of a dissolved compound such as glucose, or temperature and are used with Computational Flow Dynamics (CFD) to produce the ground truth model for comparison. A predetermined threshold level may be based on ISO standards. Adjustments may be made until a pass score is returned. The method may be used with scanners using e.g. MRI or PET techniques, and may be applicable to a diffusion or perfusion phantom.



traducir


 

Distributed system architecture for continuous glucose monitoring

NºPublicación: AU2016261830A1 24/08/2017

Solicitante:
DEXCOM INC

Resumen de: AU2016261830A1

The present disclosure relates to techniques for receiving glucose data from a continuous glucose sensor and controlling the use and redistribution of that data so it is used in an intended manner. In one aspect, a method includes preparing data including glucose levels using a continuous glucose sensor unit; wirelessly transmitting the data relating to the glucose levels to a display device from the continuous glucose sensor unit; automatically forwarding the data relating to the glucose levels from the display device to a cloud computing architecture; and storing the data relating to the glucose levels in separate groups at the cloud computing architecture.



traducir


 

EXTENDED ANALYTICAL PERFORMANCE OF CONTINUOUS GLUCOSE MONITORING DEVICES VIA NITRIC OXIDE

NºPublicación: US2017238852A1 24/08/2017

Solicitante:
UNIV NORTH CAROLINA CHAPEL HILL [US]

Resumen de: US2017238852A1

The present invention relates to instruments and methods related to the in vivo analytical performance of percutaneously implanted nitric oxide (NO)-releasing amperometric glucose biosensors. Needle-type glucose biosensors can be functionalized with NO-releasing polyurethane coatings designed to release similar total amounts of NO for rapid or slower (greater than 3 day) durations and remain functional as outer glucose sensor membranes. Relative to controls, NO-releasing sensors were characterized with improved numerical accuracy on days 1 and 3. Furthermore, the clinical accuracy and sensitivity of rapid NO-releasing sensors were superior to control and slower NO-releasing sensors at both 1 and 3 days implantation. In contrast, the slower, extended NO releasing-sensors were characterized by shorter sensor lag times (<4.2 min) in response to intravascular glucose tolerance tests versus burst NO-releasing and control sensors (>5.8 min) at 3, 7, and 10 d. Collectively, these results highlight the potential for NO release to enhance the analytical utility of in vivo glucose biosensors. Thus, the analytical performance benefit is dependent on the NO-release duration.



traducir


 

Smart Bag Used in Sensing Physiological and/or Physical Parameters of Bags Containing Biological Substance

NºPublicación: US2017239404A1 24/08/2017

Solicitante:
FREMON SCIENT INC [US]

Resumen de: US2017239404A1

The present technology discloses a cost-effective, single use bag or container for storing biological substances that incorporates on its inner wall an electronic device that is configured to measure physiological and/or physical parameters of the enclosed biological substances, such as source history, identification, demographics, time stamping, temperature, pH, conductivity, glucose, O2, CO2 levels etc. The electronic device of the disclosed bag comprises a sensor configured to measure physiological and/or physical parameters of the biological substances enclosed within the bag, and a radio-frequency (RF) device communicably coupled to the sensor and configured to: (a) acquire from the sensor data associated with the measured parameters, (b) store the acquired sensor data in nonvolatile memory, and (c) communicate the stored data wirelessly to a RF reader.



traducir


 

SYSTEMS AND METHODS FOR PERIPHERAL NERVOUS STIMULATION FOR METABOLIC AND ENDOCRINE FUNCTION

NºPublicación: US2017239484A1 24/08/2017

Solicitante:
VERILY LIFE SCIENCES LLC [US]

Resumen de: US2017239484A1

Systems and methods are provided for neuro stimulation. In one implementation, a system is provided that includes a stimulator introduced into tissue at a target location and a central controller that communicates wirelessly with the stimulator. The stimulator includes a power system that receives wireless energy transmission, and an electrode system that transmits an electrical pulse for stimulating the target location. The central controller includes a power system that wirelessly delivers power to the stimulator, a communication system that wirelessly communicates with the stimulator, and a processing system that controls the power system and the communication system. The central controller may instruct the stimulator to transmit one or more electrical pulses to the target location to affect an endocrine function (e.g., affect the glucose level of a patient).



traducir


 

HUMAN METABOLIC CONDITION MANAGEMENT

NºPublicación: US2017242975A1 24/08/2017

Solicitante:
KAHLBAUGH BRADLEY E [US]

Resumen de: US2017242975A1

Systems and methods for extracting blood glucose patterns and suggesting a behavior may include receiving, at a computing device comprising a processor, temporal data including information regarding glucose readings; identifying, by the computing device, at least one pattern based on metabolite levels extracted from the temporal data the model including variables corresponding to each of the patterns; formulating, by the computing device, a model for predicting a metabolic response; and storing the model on a data storage device. Based on the model, the behavior may be suggested to maintain a blood glucose level within a desired range.



traducir


 

AUXILIARY CLAMP USED FOR NON-INVASIVE MEASUREMENT OF BLOOD GLUCOSE CONCENTRATION

NºPublicación: WO2017140025A1 24/08/2017

Solicitante:
SHENZHEN SHENGBIZHI SCIENCE AND TECH DEV CO LTD [CN]

Resumen de: WO2017140025A1

Provided is an auxiliary clamp used for non-invasive measurement of blood glucose concentration, comprising a control line, an emitting part, a spring (4), a rotary shaft (5), a receiving part, and a controller (14). The control line comprises an emission control line (1) and a reception control line (13); the emitting part comprises an emitting clamp base (2), an emitting clamp cover (3), and an emitting triode (8); the receiving part comprises a receiving clamp base (11), a receiving clamp cover (12), and a receiving triode (9); the emitting clamp base (2) is connected to the receiving clamp base (11) by means of the rotary shaft (5); by means of the spring (4), the emitting clamp base and the receiving clamp base (11) clamp the muscle or tissue of a user, making it convenient for the user to use; a plastic sleeve (6) reduces the effect of external light causing errors when determining blood sugar content; infrared light of a particular wavelength is emitted by means of the controller (14), the emission control line (1), and the emitting triode (8); by way of the muscle tissue of the user, the infrared light is sent to the receiving triode (9) and the receiving control line (13) transmits it to the controller (14), thus obtaining the blood sugar content of the blood in the muscle tissue of the user. The auxiliary clamp is capable of aiding the determination of the current blood sugar level of the user.



traducir


 

SENSOR AND DEVICE FOR LIFETIME IMAGING AND DETECTION APPLICATIONS

NºPublicación: WO2017143129A1 24/08/2017

Solicitante:
TESSERACT HEALTH INC [US]

Resumen de: WO2017143129A1

A method of luminance lifetime imaging includes receiving incident photons at an integrated photodetector from luminescent molecules. The incident photons being received through one or more optical components of a point-of-care device. The method also includes detecting arrival times of the incident photons using the integrated photodetector. A method of analyzing blood glucose includes detecting luminance lifetime characteristics of tissue using, at least in part, an integrated circuit that detects arrival times of incident photons from the tissue. The method also includes analyzing blood glucose based upon the luminance lifetime characteristics.



traducir


 

NON-INVASIVE AUXILIARY DEVICE FOR DETECTING BLOOD GLUCOSE CONCENTRATION

NºPublicación: WO2017140116A1 24/08/2017

Solicitante:
ANYCHECK INFORMATION TECH CO LTD [CN]

Resumen de: WO2017140116A1

A non-invasive auxiliary device for detecting blood glucose concentration, comprising control lines, a transmitting member, a spring (4), a rotating shaft (5), a receiving member and a controller (14). The control line comprises a transmission control line (1) and a reception control line (13); the transmitting member comprises a transmitting holder (2), a transmitting holder cover (3) and a transmitting triode (8). The receiving member comprises a receiving holder (11), a receiving holder cover (12) and a receiving triode (9). The transmitting holder (2) is connected with the receiving holder (11) by means of the rotating shaft (5). Muscles or tissues of a user are tightly clamped by means of the spring (4), transmitting holder (2) and receiving holder (11), thereby facilitating the user's operations. The auxiliary device provide assistance in determining a current blood glucose level of the user.



traducir


 

A METHOD AND APPARATUS FOR MEASURING THE CONCENTRATION OF TARGET SUBSTANCES IN BLOOD

NºPublicación: WO2017141024A2 24/08/2017

Solicitante:
ORSUS MEDICAL LTD [GB]

Resumen de: WO2017141024A2

A non-invasive testing apparatus for determining a concentration of a target substance, such as blood sugar,blood alcohol, cholesterol,etc.,in a patient's blood is disclosed. The apparatus and method involve applying an output RF signal (102) to the skin of a patient via an antenna(20), and measuring the amplitude and phase of a response signal, which is a function of the output RF signal (102) modified by an interaction with the patient's blood. The invention takes measurements at different output RF frequencies (310), and plots the response (300) as a function of frequency (310). The invention is essentially characterised by deriving various derived parameters (552, 554, 556, 550, 408, 410) from the shape of the resulting plots, namely any or more of: a resonance frequency shift; a Q factor of the resonance; a group delay; a phase shift; an amplitude variation; a shape factor of the plot; and a gradient of the plot at different frequencies. The invention utilises models of the derived parameters as a function of concentration of the target substance in blood to arrive at a determination of the latter. Also disclosed is a novel circuit (1000) for obtaining the amplitude and phase measurements, a calibration device (5008), and various improvements relating to wearable non- invasive testing apparatus (3000, 4000).



traducir


 

CONTINUOUS GLUCOSE COLLECTING APPARATUS AND MAIN MACHINE

NºPublicación: EP3207871A1 23/08/2017

Solicitante:
SHENZHEN WAVEGUIDER OPTICAL TELECOM TECH INC [CN]

Resumen de: EP3207871A1

A dynamic blood glucose data acquiring device and a host are provided, wherein the collecting device comprises a portable host and a probe assembly; the probe assembly includes two glucolase micro electrode needles and a first circuit board; a first electrode terminal is provided on the first circuit board; the host includes an outer shell and a second circuit board which is located in the outer shell, and a second electrode terminal is provided on the second circuit board; the outer shell further includes a probe mounting position and a fixing structure for fixing the outer shell to a human body; the probe assembly is mounted into the probe mounting position in such a way that the glucolase micro electrode needles are projected out of a lower surface of the outer shell; when the probe assembly is mounted into the probe mounting position, the first electrode terminal on the first circuit board is electrically connected to the second electrode terminal on the second circuit board. In the present application, the probe assembly is fixed on the human body via the portable host, and the blood glucose signals are acquired via the glucolase micro electrode needles of the probe assembly, the collection, the processing and the output of the blood glucose signals can be achieved as a result.



traducir


 

BLOOD-GLUCOSE LEVEL MANAGEMENT SYSTEM

NºPublicación: HK1192947A1 18/08/2017

Solicitante:
TERUMO CORP [JP]

Resumen de: WO2012133221A1

Provided is a blood-glucose level management system (101) which can systematically collect blood-glucose level data from multiple blood-glucose meters of different types and manage the blood-glucose level data centrally. A terminal (401) of the blood-glucose level management system (101) differentiates a blood-glucose meter (103) for use in wards from a personal blood-glucose meter (102) by inquiring the model name in the initial stage of communication. In case of a blood-glucose level meter (103) for use in wards, blood-glucose level data are immediately downloaded and uploaded to a server (104), while in case of a personal blood-glucose level meter (102), the patient ID or the serial number is retrieved through a bar-code reader (405) or an operation unit (412), and then the patient ID is linked to the blood-glucose level data. The blood-glucose level management system (101) is so configured as to include the above processing steps. Therefore, the blood-glucose level management system (101) enables: handling of both a blood-glucose level meter (103) for use in wards and a personal blood-glucose level meter (102) by a common system; and systematic central management of blood-glucose levels of all patients.



traducir


 

SENSOR AND DEVICE FOR LIFETIME IMAGING AND DETECTION APPLICATIONS

NºPublicación: US2017231500A1 17/08/2017

Solicitante:
TESSERACT HEALTH INC [US]

Resumen de: US2017231500A1

A method of luminance lifetime imaging includes receiving incident photons at an integrated photodetector from luminescent molecules. The incident photons being received through one or more optical components of a point-of-care device. The method also includes detecting arrival times of the incident photons using the integrated photodetector. A method of analyzing blood glucose includes detecting luminance lifetime characteristics of tissue using, at least in part, an integrated circuit that detects arrival times of incident photons from the tissue. The method also includes analyzing blood glucose based upon the luminance lifetime characteristics.



traducir


 

Diagnostic Transceiver Assembly

NºPublicación: US2017232193A1 17/08/2017

Solicitante:
GARGANO PAUL [US]

Resumen de: US2017232193A1

A diagnostic transceiver assembly includes a diagnostic unit that may be implanted into a human body. The diagnostic unit monitors physiological functions of the human body to include heart rate and blood serum levels. The diagnostic unit generates a diagnostic sequence when the diagnostic unit detects blood serum levels outside of a trigger ratio. A dispensing unit may be implanted into the human body. The dispensing unit is in fluid communication with the human circulatory system. The dispensing unit contains insulin. The dispensing unit releases a measured amount of the insulin into the human circulatory system in response to the diagnostic sequence.



traducir


 

Diabetic Medication Delivery Pen Packet

Nº publicación: US2017232184A1 17/08/2017

Solicitante:
BIHN HUNTER S [US]

Resumen de: US2017232184A1

A packet for a medication delivery pen comprises a pen cap integrally connected to one, some, or all of the devices listed: an unused pen needle dispenser, sharps container for used needles, folding glucose monitor, constant glucose monitor, glucose tablets/candy, lancing device, or glucose test strip holder. The integrated pen cap is configured to replace the pen cap normally supplied with the pen and the attachments and devices featured put all items needed by a diabetic in one device. This device also gives the diabetic freedom in choosing which devices they would like to or would like not to carry with them, and in what manner so as to have the highest convenience to the diabetic.


traducir



 

previousPage Página2 de 4 nextPage Mostrar por página

Volver